Tonix Pharmaceuticals, Inc. and Tonix Pharma Limited v. Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc., No. 3:26-cv-14677 (D.N.J.), is a Hatch-Waxman patent complaint filed November 13, 2026. The complaint says Tonix Pharmaceuticals, Inc. is a Delaware corporation with a principal place of business in Berkeley Heights, New Jersey, and is the holder of approved New Drug Application No. 219428. It says Tonix Pharma Limited is a company organized under the laws of Ireland, with a principal place of business in Dun Laoghaire, Dublin, Ireland, is a wholly owned subsidiary of Tonix Pharmaceuticals, Inc., and is the owner by assignment of the four asserted patents. It alleges, on information and belief, that Dr. Reddy's Laboratories Ltd. is a corporation organized under the laws of India, with a principal place of business in Hyderabad, India, and that Dr. Reddy's Laboratories, Inc. is a New Jersey corporation with a principal place of business in Princeton, New Jersey, and is a wholly owned subsidiary of Dr. Reddy's Laboratories Ltd. The case is assigned to Judge Claire C. Cecchi.
The patents and the ANDA
The complaint asserts four patents, each titled Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride: U.S. Patent 9,636,408, issued May 2, 2017; U.S. Patent 9,956,188, issued May 1, 2018; U.S. Patent 10,117,936, issued November 6, 2018; and U.S. Patent 10,864,175, issued December 15, 2020. It says the FDA approved NDA No. 219428 for TONMYA (cyclobenzaprine hydrochloride sublingual tablets) for the treatment of fibromyalgia in adults on August 15, 2025, and that the four patents were listed in the Orange Book with respect to TONMYA.
As the complaint quotes them, claim 1 of the '408 patent recites a pharmaceutical composition comprising a eutectic composition of 25% plus or minus 2% by weight of mannitol and 75% plus or minus 2% by weight of cyclobenzaprine HCl that melts at 143 degrees C plus or minus 3 degrees C; claim 1 of the '188 patent recites a eutectic of mannitol and cyclobenzaprine HCl comprising 75% plus or minus 2% cyclobenzaprine HCl and 25% plus or minus 2% mannitol by weight; claim 1 of the '936 patent recites a pharmaceutical composition comprising a eutectic of the same proportions in which the mannitol is beta-mannitol or delta-mannitol; and claim 1 of the '175 patent recites a eutectic of cyclobenzaprine HCl and beta-mannitol in the same proportions. The complaint describes TONMYA as a composition containing a eutectic of cyclobenzaprine hydrochloride and mannitol, in sublingual tablets that dissolve under the tongue.
The complaint alleges, on information and belief, that the two defendants acted in concert to prepare and submit ANDA No. 221664, and that on or before September 29, 2026, Dr. Reddy's Laboratories, Inc., with the active involvement of Dr. Reddy's Laboratories Ltd., submitted it under 21 U.S.C. § 355(j), seeking approval to engage in the commercial manufacture, importation, use, offer for sale, marketing, and sale of proposed generic cyclobenzaprine hydrochloride sublingual tablets, referencing TONMYA as the reference listed drug. It says Dr. Reddy's sent Tonix a Paragraph IV notice dated September 29, 2026, stating that the ANDA seeks approval before the asserted patents expire, and that Tonix first received the notice on October 1, 2026. The notice, according to the complaint, asserts that the patents-in-suit are invalid, unenforceable, and not infringed by the proposed ANDA product. The complaint also alleges that the notice's offer of confidential access to the ANDA imposed unreasonable restrictions and did not comply with the Hatch-Waxman Act, citing among other things the exclusion of Tonix's in-house legal representatives and a 30-month prosecution bar concerning cyclobenzaprine.
The counts and the prayer
Counts I, III, V, and VII allege that submission of the ANDA infringes the '408, '188, '936, and '175 patents, respectively, under 35 U.S.C. § 271(e)(2)(A), and that if the FDA approves the ANDA, the defendants will infringe at least claim 1 of each patent by commercial manufacture, use, sale, or importation of the proposed ANDA product, or by inducing or contributing to infringement by others. They allege, on information and belief, that the proposed product will substantively copy the TONMYA label, is a eutectic composition of cyclobenzaprine HCl, contains mannitol or an equivalent in an amount sufficient to form a eutectic, and, subject to Tonix's ongoing investigation, meets the other claim elements, and that patients and healthcare professionals will use it according to its labeling in an infringing manner. Each of these counts alleges that a launch before the patent expires would cause immediate and irreparable harm and that the infringement is willful. Counts II, IV, VI, and VIII seek declaratory judgments under 28 U.S.C. §§ 2201 and 2202 that commercial manufacture, use, marketing, offer for sale, sale, or importation of the proposed ANDA product would infringe at least claim 1 of the same four patents.
The prayer asks for a judgment that the defendants have infringed each patent and a declaration that commercial manufacture, use, marketing, offer for sale, sale, or importation of the proposed ANDA product would infringe each patent; an order under 35 U.S.C. § 271(e)(4)(A) that the effective date of any approval of ANDA No. 221664 shall not be earlier than the latest expiration date, including any applicable extensions, of any patent-in-suit found infringed; a permanent injunction under §§ 271(e)(4)(B) and 283; damages or other monetary relief, including treble damages and prejudgment interest, if the defendants engage in commercial activity before expiration; a declaration that the case is exceptional and an award of attorney's fees under 35 U.S.C. § 285; and costs and expenses.
Jurisdiction and venue
The complaint alleges that the court has subject matter jurisdiction under 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202, and that venue is proper as to Dr. Reddy's Laboratories, Inc. under 28 U.S.C. §§ 1391 and 1400(b) and as to Dr. Reddy's Laboratories Ltd. under 28 U.S.C. § 1391(c)(3).
What to watch next
Watch for the defendants' answer, a Rule 12 motion, or a scheduling order. The case can end at any time, including by settlement or voluntary dismissal.